Veridex to expand circulating tumour cell testing to aid drug development
This article was originally published in Scrip
Executive Summary
Veridex is teaming up with the Massachusetts General Hospital (MGH) to develop the next-generation of its circulating tumour cell (CTC) technology for capturing tumour cells in patients' blood. The goal is to develop a bench top system that will allow CTCs to be used as a tool for therapeutic decision making and for drug discovery and development applications.